Rosiglitazone

Drug Profile

Rosiglitazone

Alternative Names: Avandia; BRL 49653; BRL 49653C; Rosiglitazone extended-release; Rosiglitazone maleate; Rosiglitazone XR; RSG XR

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Bristol-Myers Squibb; GlaxoSmithKline
  • Class Antidementias; Antihyperglycaemics; Antipsoriatics; Small molecules; Thiazolidinediones
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Asthma
  • Discontinued Alzheimer's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Nov 2013 US FDA removes restrictions for use of rosiglitazone-containing drugs in Type 2 diabetes mellitus in the USA
  • 06 Jun 2013 Joint advisory committee to the FDA recommends that rosiglitazone remain available to appropriate patients in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top